Discover a study which demonstrates how rocatinlimab has shown significant improvements in treating durable atopic dermatitis ...

Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and ...

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical ...

The following is a summary of “Using smartphone data to frequently measure atopic dermatitis severity and understand triggers ...

Discover the study that, at week 16, showed how dupilumab demonstrated significant benefits compared to placebo, regardless ...

Upadacitinib has higher rates of rapid, sustained efficacy for the treatment of atopic dermatitis across several body regions when compared with dupilumab, but upadacitinib also had a higher rate of ...

AnaptysBio’s drug candidates rosnilimab and ANB032 hold key trial results ahead. Find out why ANAB stock is impacted by ...

For the millions of people who suffer from atopic dermatitis (AD), or eczema, ENS-002 represents a potential paradigm shift ...

Hyperkeratotic hand dermatitis is more common in men and ... and scabies need to be excluded (MennE9, 2000). Treatment/management. Due to a marked propensity for relapse, exacerbations, chronicity ...

Andrew Rosenberg, DVM, DACVD, discusses the effectiveness of JAK inhibitors for treating allergy symptoms in animals ...

The company has shown significant progress with its lead asset, soquelitinib, particularly in treating atopic dermatitis (AtD). The upcoming interim Phase 1 data, expected in December, has generated ...